Efracea

How to order Efracea

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Efracea on Prescriptsy

Efracea is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Efracea is a prescription-only medicine containing doxycycline 40 mg in a modified-release capsule, specifically formulated for the treatment of papulopustular rosacea in adults.

Rosacea is a common chronic inflammatory skin condition affecting the central face, characterised by persistent redness (erythema), visible blood vessels (telangiectasia), and, in the papulopustular subtype, inflammatory papules (red bumps) and pustules (spots containing pus).

Efracea uses doxycycline at a sub-antimicrobial dose, meaning it provides anti-inflammatory benefits without acting as an antibiotic and without contributing to antibiotic resistance.

Rosacea affects an estimated 1 in 10 people in the UK, though many cases go undiagnosed.

It most commonly presents between the ages of 30 and 50 and is more frequently recognised in people with fair skin, although it occurs in all skin types.

The condition tends to follow a relapsing and remitting course, with flares triggered by factors such as sun exposure, temperature extremes, alcohol, spicy food, stress, and certain skincare products.

While rosacea is not dangerous, the visible facial inflammation can cause significant psychological distress, affecting self-esteem, social confidence, and quality of life.

This page provides a detailed clinical overview of Efracea, including how it works, who it is suitable for, dosage instructions, expected results, side effects, important safety information, and how to obtain a prescription in the United Kingdom.

Important safety information about Efracea

Before reading further, note the following essential safety points. Efracea is a prescription-only medicine (POM) and must be used as directed by your prescriber.

• Efracea must not be taken during pregnancy or breastfeeding. Doxycycline can permanently discolour developing teeth and affect foetal bone growth.
• Efracea must not be used in children or adolescents under 18 years.
• Take the capsule with a full glass of water in an upright position. Do not lie down for at least 30 minutes after taking it, to avoid oesophageal irritation.
• Avoid prolonged sun exposure and use sunscreen, as doxycycline increases photosensitivity.
• Do not take Efracea concurrently with oral retinoids such as isotretinoin.

Understanding rosacea

Rosacea is classified into several subtypes, although these often overlap. Erythematotelangiectatic rosacea involves persistent central facial redness and visible blood vessels.

Papulopustular rosacea adds inflammatory papules and pustules to the redness, often mistaken for acne but lacking the comedones (blackheads and whiteheads) that characterise acne vulgaris.

Phymatous rosacea involves skin thickening, particularly of the nose (rhinophyma). Ocular rosacea affects the eyes, causing dryness, grittiness, blepharitis, and conjunctivitis.

Efracea is specifically indicated for the papulopustular subtype.

The inflammatory papules and pustules are driven by dysregulation of the innate immune system, abnormal neurovascular signalling, and the activity of the skin mite Demodex folliculorum, which is found in higher densities on rosacea-affected skin.

Matrix metalloproteinases (MMPs), particularly MMP-9, are elevated in rosacea lesions and contribute to tissue remodelling, vascular changes, and the characteristic inflammatory response.

The distinction from acne is important: rosacea typically affects the central face (cheeks, nose, chin, and central forehead) in adults over 30, lacks comedones, and is often accompanied by flushing, stinging, and sensitivity.

Treatment approaches differ from those used for acne.

How Efracea works: sub-antimicrobial anti-inflammatory action

The concept behind Efracea is a deliberate departure from traditional antibiotic therapy for rosacea.

For decades, dermatologists prescribed doxycycline at standard antibiotic doses (100 mg or 200 mg daily) to treat rosacea, and it was effective.

However, this approach contributed to antibiotic resistance, a growing public health concern.

Research identified that the beneficial effect of doxycycline in rosacea is primarily anti-inflammatory rather than antimicrobial, and that these anti-inflammatory effects occur at plasma concentrations below those needed to inhibit bacterial growth.

The modified-release 40 mg capsule delivers 30 mg as immediate release and 10 mg as delayed release, producing steady plasma levels in the anti-inflammatory range throughout the day.

At this concentration, doxycycline inhibits matrix metalloproteinases (MMPs), particularly MMP-9, reduces the production of inflammatory cytokines (interleukin-1 beta, tumour necrosis factor alpha), and modulates neutrophil chemotaxis and reactive oxygen species generation.

These actions collectively reduce the inflammatory component of rosacea without exerting selective pressure on bacteria.

Clinical studies have demonstrated that 40 mg modified-release doxycycline does not affect the normal bacterial flora of the skin, gut, or urogenital tract, and does not promote the emergence of antibiotic-resistant organisms.

This is a significant advantage over traditional antibiotic dosing.

Clinical evidence and UK prescribing guidance

Efracea's efficacy was established in two pivotal phase III randomised, double-blind, placebo-controlled trials involving over 500 patients with moderate to severe papulopustular rosacea (10 to 40 inflammatory lesions).

Patients treated with Efracea showed a statistically significant reduction in inflammatory lesion count compared with placebo, with meaningful improvement evident from week 3 and continuing throughout the 16-week treatment period.

The mean reduction in inflammatory lesions was approximately 60% by week 16.

British Association of Dermatologists (BAD) guidelines on rosacea management recommend topical treatments (metronidazole, azelaic acid, or ivermectin) as first-line therapy for mild to moderate papulopustular rosacea, with the addition of oral therapy for moderate to severe cases or those not responding to topical treatment alone.

Sub-antimicrobial dose doxycycline (Efracea) is positioned as a preferred oral option because of its anti-inflammatory mechanism and lack of contribution to antibiotic resistance.

NICE Clinical Knowledge Summaries on rosacea similarly recommend considering oral doxycycline for papulopustular rosacea that is not adequately controlled by topical therapy. The sub-antimicrobial formulation is preferred over full-dose antibiotics when available and appropriate.

Dosage and administration

Take one Efracea 40 mg modified-release capsule once daily, preferably in the morning. Swallow the capsule whole with a full glass of water (at least 200 mL).

Do not crush, chew, or open the capsule, as this would destroy the modified-release mechanism and potentially deliver a sudden, higher dose.

Take Efracea on an empty stomach, ideally at least one hour before breakfast or two hours after eating.

Avoid dairy products, calcium supplements, iron supplements, and antacids at the time of dosing, as divalent and trivalent cations (calcium, magnesium, iron, aluminium) bind to tetracyclines in the gut and significantly reduce absorption.

Remain in an upright position (sitting or standing) for at least 30 minutes after taking the capsule. This reduces the risk of the capsule lodging in the oesophagus and causing irritation or ulceration, a known complication of tetracycline administration.

The standard treatment course is 16 weeks. Clinical improvement typically begins at 3 to 4 weeks and continues throughout the course.

If rosacea recurs after completing treatment, your prescriber may consider a further course. Continuous long-term use should be periodically reviewed.

Side effects of Efracea

Common side effects

Because Efracea uses a sub-antimicrobial dose, gastrointestinal side effects are generally milder than with standard antibiotic doses of doxycycline.

Common effects reported in clinical trials include nasopharyngitis (symptoms of a common cold), sinusitis, diarrhoea, nausea, abdominal pain, and headache. These are typically mild and self-limiting.

Uncommon and rare side effects

Uncommon effects include dry mouth, flatulence, raised liver enzymes, photosensitivity reactions, and vaginal candidiasis (thrush).

Rare but important effects include oesophageal ulceration (if the capsule is not taken correctly), benign intracranial hypertension (pseudotumour cerebri) characterised by persistent severe headache and visual disturbances (blurred vision, double vision, visual field loss), and blood disorders including haemolytic anaemia and thrombocytopenia.

Benign intracranial hypertension is a recognised rare complication of all tetracyclines.

Symptoms include a persistent, often severe headache that may be worse on waking or on bending forward, and visual disturbances.

If these symptoms develop, stop Efracea immediately and seek urgent medical assessment, as untreated intracranial hypertension can cause permanent visual damage.

When to seek urgent medical advice

Stop taking Efracea and seek emergency care (call 999 or attend A&E) if you experience sudden severe headache with visual disturbance, difficulty breathing, severe allergic reaction (swelling of face, lips, tongue, or throat), or severe skin reaction (widespread rash with blistering).

Contact your GP or NHS 111 for persistent nausea, painful swallowing, skin rash with sun exposure, or any new symptoms that concern you.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Pregnancy and breastfeeding

Efracea is absolutely contraindicated during pregnancy and breastfeeding. Doxycycline crosses the placenta and is excreted in breast milk.

It causes permanent discolouration of developing teeth (yellowish-brown staining), enamel hypoplasia, and may impair foetal bone development.

If you become pregnant while taking Efracea, stop immediately and inform your GP.

Children and adolescents

Efracea must not be used in patients under 18 years. Tetracyclines are deposited in calcifying teeth and bones, causing permanent staining and potential growth impairment.

Photosensitivity

Doxycycline increases the skin's sensitivity to ultraviolet light.

Use a broad-spectrum sunscreen of SPF 30 or higher on exposed skin, wear a wide-brimmed hat, and avoid prolonged sun exposure and sunbeds throughout the treatment course.

Photosensitivity may present as an exaggerated sunburn reaction (redness, swelling, blistering) even after modest sun exposure.

Oesophageal irritation

All tetracyclines carry a risk of oesophageal irritation and ulceration if they lodge in the oesophagus.

This is prevented by taking the capsule with plenty of water and remaining upright for at least 30 minutes.

Patients with known oesophageal conditions should discuss the risk with their prescriber.

Interactions with other medicines

Avoid taking Efracea with oral retinoids (isotretinoin, acitretin) due to the increased risk of benign intracranial hypertension.

Tetracyclines may enhance the anticoagulant effect of warfarin; INR monitoring is advised. Absorption is reduced by antacids, calcium, magnesium, iron, and bismuth preparations.

Efracea may reduce the efficacy of some oral contraceptives; discuss additional precautions with your prescriber.

Managing rosacea alongside Efracea

Efracea addresses the inflammatory component of rosacea, but a comprehensive management plan includes trigger avoidance and appropriate skincare.

Common rosacea triggers include sun exposure, extreme temperatures (hot and cold), hot drinks, alcohol (particularly red wine), spicy food, vigorous exercise, stress, and certain skincare products (especially those containing alcohol, fragrance, or abrasive particles).

Use a gentle, fragrance-free cleanser and a non-comedogenic, fragrance-free moisturiser. Apply broad-spectrum sunscreen daily as part of your routine.

Topical treatments such as metronidazole gel, azelaic acid, or ivermectin cream may be used alongside Efracea for enhanced efficacy and may help maintain remission after the oral course is completed.

Persistent background redness and visible blood vessels (telangiectasia) do not respond to Efracea or other pharmacological treatments.

Vascular laser or intense pulsed light (IPL) therapy may be offered by dermatologists for these features. Rhinophyma (thickened nasal skin) may require surgical or laser treatment.

How to get Efracea in the UK

Efracea is a prescription-only medicine. Your GP can prescribe it for papulopustular rosacea following a clinical assessment.

In straightforward cases, referral to dermatology is not usually necessary, though it may be appropriate for severe, treatment-resistant, or diagnostically uncertain cases.

Authorised online prescribers registered with the GPhC can also prescribe Efracea following a structured consultation.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

When to see your GP about rosacea

Contact your GP or NHS 111 if your rosacea symptoms worsen despite treatment, if you develop eye symptoms (dryness, grittiness, redness, or swollen eyelids suggesting ocular rosacea), or if you notice skin thickening around the nose.

Early treatment of rosacea subtypes and complications can prevent progression. Report any adverse reactions to Efracea via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Efracea 40 mg Modified-release Hard Capsules, Summary of Product Characteristics (EMC)
• Doxycycline, British National Formulary (BNF)
• NICE CKS: Rosacea
• Rosacea, NHS
• British Association of Dermatologists, Rosacea
• MHRA Yellow Card Scheme